Sarepta upgraded at Cantor on pipeline, growth potential

Nov. 07, 2024 12:25 PM ETSarepta Therapeutics, Inc. (SRPT) StockBy: Jonathan Block, SA News Editor
(1min)

mbbirdy

  • Cantor Fitzgerald has upgraded Sarepta Therapeutics (NASDAQ:SRPT) to overweight from neutral signaling that the company's growth could be higher than the Street is estimating and citing the pharma's pipeline.
  • The firm also raised its price target to $167 from $152 (~30% upside based on

Recommended For You

Comments

Sort by

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

More Trending News

See More »

Create a free account to read the full article

Gain access to the world’s leading investment community.

Already registered?

By creating an account using any of the options above, you agree to the Terms of Use & Privacy Policy
or

About SRPT Stock

SymbolLast Price% Chg
SRPT
112.89-1.25%
Created with Highcharts 11.2.0Nov 8Nov 11Nov 12Nov 13110120130
Market Cap
$10.92B
PE (FWD)
52.56
Yield
-
Rev Growth (YoY)
48.45%
Short Interest
5.92%
Prev. Close
$114.32
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SRPT112.89-1.25%
Sarepta Therapeutics, Inc.
EXEL35.66-0.53%
Exelixis, Inc.
RVMD58.42-1.53%
Revolution Medicines, Inc.
BMRN66.801.01%
BioMarin Pharmaceutical Inc.
INSM70.620.68%
Insmed Incorporated
Compare

Trending Analysis

See All Analysis »

Trending News

See All News »